HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

riferminogene pecaplasmide

a fibroblast growth factor 1 gene therapy for the treatment of peripheral arterial disorders

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Intercellular Signaling Peptides and Proteins: 29768
    - Fibroblast Growth Factors: 2575
      - Fibroblast Growth Factor 1: 753
        riferminogene pecaplasmide: 1
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Fibroblast Growth Factors: 2575
      - Fibroblast Growth Factor 1: 753
        riferminogene pecaplasmide: 1
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Fibroblast Growth Factors: 2575
    - Fibroblast Growth Factor 1: 753
      - riferminogene pecaplasmide: 1

Related Diseases

1.	Chronic Limb-Threatening Ischemia 01/01/2010 - "Sanofi-aventis is developing riferminogene pecaplasmide, a fibroblast growth factor 1 (FGF-1; NV1FGF) gene therapy for the treatment of peripheral arterial disorders (PAD) such as critical limb ischemia. "

Related Drugs and Biologics

1.	Fibroblast Growth Factor 1 (FGF-1)